Orchestra BioMed Holdings, Inc. Ordinary Shares OBIO
i
Market dataready · fetched 2026-11-12T04:07:35.632Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:00.856503195Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T04:07:35.268983+00:00
Orchestra BioMed Holdings, Inc. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.84 | 582.1% | 51.8% | |||
| 25Δ | 4.42 | 554.2% | 46.2% | |||
| 30Δ | 5.00 | 526.3% | 40.7% | |||
| 35Δ | 5.58 | 498.3% | 35.1% | |||
| 40Δ | 6.16 | 470.4% | 29.6% | |||
| 45Δ | 6.74 | 442.4% | 24.0% | |||
| 50Δ | 7.32 | 414.5% | 18.5% | |||
| 55Δ | 7.74 | 390.5% | 15.4% | |||
| 60Δ | 5.91 | 119.6% | 10.4% | 8.09 | 368.2% | 13.3% |
| 65Δ | 5.73 | 119.3% | 8.7% | 8.44 | 345.8% | 11.2% |
| 70Δ | 5.56 | 119.1% | 7.0% | 8.78 | 323.5% | 9.1% |
| 75Δ | 5.39 | 118.8% | 5.3% | 9.13 | 301.2% | 7.0% |
| 80Δ | 5.21 | 118.6% | 3.6% | 9.48 | 278.9% | 5.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.84
- IV
- 582.1%
- B/E move
- 51.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.42
- IV
- 554.2%
- B/E move
- 46.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.00
- IV
- 526.3%
- B/E move
- 40.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.58
- IV
- 498.3%
- B/E move
- 35.1%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.16
- IV
- 470.4%
- B/E move
- 29.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.74
- IV
- 442.4%
- B/E move
- 24.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.32
- IV
- 414.5%
- B/E move
- 18.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.74
- IV
- 390.5%
- B/E move
- 15.4%
60Δ
- Pseudo strike
- 5.91
- IV
- 119.6%
- B/E move
- 10.4%
- Pseudo strike
- 8.09
- IV
- 368.2%
- B/E move
- 13.3%
65Δ
- Pseudo strike
- 5.73
- IV
- 119.3%
- B/E move
- 8.7%
- Pseudo strike
- 8.44
- IV
- 345.8%
- B/E move
- 11.2%
70Δ
- Pseudo strike
- 5.56
- IV
- 119.1%
- B/E move
- 7.0%
- Pseudo strike
- 8.78
- IV
- 323.5%
- B/E move
- 9.1%
75Δ
- Pseudo strike
- 5.39
- IV
- 118.8%
- B/E move
- 5.3%
- Pseudo strike
- 9.13
- IV
- 301.2%
- B/E move
- 7.0%
80Δ
- Pseudo strike
- 5.21
- IV
- 118.6%
- B/E move
- 3.6%
- Pseudo strike
- 9.48
- IV
- 278.9%
- B/E move
- 5.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 125.35% |
Biotechnology
OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern,…
More →OCS
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug,…
More →OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its…
More →OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company…
More →OMER
Description unavailable
More →ONC
Description unavailable
More →